Iranian Journal of Pediatrics

Published by: Kowsar

Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma?

Nurdan Tacyildiz 1 , Hikmet Gulsah Tanyildiz 1 , * , Handan Ugur Dincaslan 1 , Gulsan Yavuz 1 , Emel Unal 1 , Elgin Ozkan 2 , Cigdem Soydal 2 , Ozlem Kucuk 2 and Yusuf Yildiz 3
Authors Information
1 Department of Pediatric Oncology, School of Medicine, Ankara University, Ankara, Turkey
2 Department of Nuclear Medicine, School of Medicine, Ankara University, Ankara, Turkey
3 Department of Orthopedics, School of Medicine, Ankara University, Ankara, Turkey
Article information
  • Iranian Journal of Pediatrics: April 30, 2016, 26 (2); e4008
  • Published Online: March 5, 2016
  • Article Type: Research Article
  • Received: September 5, 2015
  • Revised: November 6, 2015
  • Accepted: December 1, 2015
  • DOI: 10.5812/ijp.4008

To Cite: Tacyildiz N, Tanyildiz H G, Dincaslan H U, Yavuz G, Unal E, et al. Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma?, Iran J Pediatr. 2016 ; 26(2):e4008. doi: 10.5812/ijp.4008.

Copyright © 2016, Growth & Development Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods:
4. Results
5. Discussion
  • 1. Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med. 2008; 49(12): 1928-35[DOI][PubMed]
  • 2. Dimitrakopoulou-Strauss A, Strauss LG, Heichel T, Wu H, Burger C, Bernd L, et al. The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med. 2002; 43(4): 510-8[PubMed]
  • 3. Charest M, Hickeson M, Lisbona R, Novales-Diaz JA, Derbekyan V, Turcotte RE. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur J Nucl Med Mol Imaging. 2009; 36(12): 1944-51[DOI][PubMed]
  • 4. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008; 49(3): 480-508[DOI][PubMed]
  • 5. Lan XL, Zhang YX, Wu ZJ, Jia Q, Wei H, Gao ZR. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions. Clin Radiol. 2008; 63(7): 756-64[DOI][PubMed]
  • 6. Muheremu A, Niu X. Positron emission tomography/computed tomography for bone tumors (Review). Oncol Lett. 2015; 9(2): 522-6[DOI][PubMed]
  • 7. Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2008; 26(3): 399-405[DOI][PubMed]
  • 8. Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, Ingle AM, et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res. 2012; 18(21): 6011-22[DOI][PubMed]
  • 9. Navid F, Baker SD, McCarville MB, Stewart CF, Billups CA, Wu J, et al. Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clin Cancer Res. 2013; 19(1): 236-46[DOI][PubMed]
  • 10. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005; 23(9): 2004-11[DOI][PubMed]
  • 11. Shaheen M, Deheshi BM, Riad S, Werier J, Holt GE, Ferguson PC, et al. Prognosis of radiation-induced bone sarcoma is similar to primary osteosarcoma. Clin Orthop Relat Res. 2006; 450: 76-81[DOI][PubMed]
  • 12. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol. 2008; 26(4): 633-8[DOI][PubMed]
  • 13. Grignani G, Palmerini E, Dileo P, Asaftei SD, D'Ambrosio L, Pignochino Y, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012; 23(2): 508-16[DOI][PubMed]
  • 14. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009; 27(19): 3133-40[DOI][PubMed]
  • 15. Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000; 18(17): 3108-14[PubMed]
  • 16. Wagner LM, Crews KR, Iacono LC, Houghton PJ, Fuller CE, McCarville MB, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res. 2004; 10(3): 840-8[PubMed]
  • 17. Wagner LM, McAllister N, Goldsby RE, Rausen AR, McNall-Knapp RY, McCarville MB, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer. 2007; 48(2): 132-9[DOI][PubMed]
  • 18. Lakkaraju A, Patel CN, Bradley KM, Scarsbrook AF. PET/CT in primary musculoskeletal tumours: a step forward. Eur Radiol. 2010; 20(12): 2959-72[DOI][PubMed]
  • 19. Treglia G, Salsano M, Stefanelli A, Mattoli MV, Giordano A, Bonomo L. Diagnostic accuracy of (1)(8)F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis. Skeletal Radiol. 2012; 41(3): 249-56[DOI][PubMed]
  • 20. Caldarella C, Salsano M, Isgro MA, Treglia G. The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma. Int J Mol Imaging. 2012; 2012: 870301[DOI][PubMed]
  • 21. Quartuccio N, Fox J, Kuk D, Wexler LH, Baldari S, Cistaro A, et al. Pediatric bone sarcoma: diagnostic performance of (1)(8)F-FDG PET/CT versus conventional imaging for initial staging and follow-up. AJR Am J Roentgenol. 2015; 204(1): 153-60[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments